Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
Silo Pharma (Nasdaq: SILO) said it hired Resyca to run a drug-device robustness study for SPC-15, its intranasal nose-to-brain PTSD prophylactic using a microchip-based nasal spray. The 30-day study will assess device performance and formulation stability to support a planned FDA Type C meeting request on IND strategy and Phase 1 design.
How this was made
The 30-second read
Why it matters
The company frames the robustness study as supporting an FDA Type C meeting request to obtain guidance on IND strategy and Phase 1 trial design, following a prior pre-IND alignment on a 505(b)(2) pathway.
Market read
This is a concrete pre-IND milestone step (robustness study engagement and 30-day evaluation plan) intended to reduce regulatory uncertainty for SPC-15’s first-in-human program.
What to watch
Key risk is whether the robustness study outcomes (not yet provided) satisfy expectations for device performance and formulation stability; any issues could delay the IND/Phase 1 timeline.
Background
Silo Pharma is developing SPC-15, an intranasal prophylactic for PTSD, using a microchip-based nose-to-brain delivery system via Resyca’s Soft-Mist Nasal Spray.
Ticker impact
Silo Pharma engaged Resyca for a 30-day robustness study of SPC-15’s nose-to-brain microchip nasal spray ahead of an FDA Type C meeting request.
Near-term sentiment likely modestly positive as it advances preclinical-to-IND readiness, but magnitude is likely limited given no clinical data or FDA decision is disclosed.
The article discloses a concrete development step (robustness study scope/timeline) tied to a planned FDA Type C meeting, which can de-risk IND planning; however, it does not provide results, FDA outcomes, or financial terms.
Market effects
Highlights combination-product (drug-device) development requirements for intranasal CNS therapies, potentially reinforcing investor focus on IND-readiness milestones.
No specific regional market impact beyond US biotech regulatory process.
US FDA interaction planning can influence global development timelines for similar nose-to-brain CNS programs.
Counterpoint
Robustness testing is a standard step; without disclosed results or FDA confirmation, the market may treat this as incremental rather than a catalyst.
Key entities
- companySilo Pharma
Nasdaq-listed developmental-stage biopharmaceutical company advancing SPC-15 for PTSD.
- partnerResyca
Drug-device development partner conducting the robustness study for the SPC-15 nasal spray system.
- regulatorFDA
US regulator to be engaged via a Type C meeting request for IND strategy and Phase 1 design guidance.
